Latest News
New Employees

New Employees

Chem-Labs Limited is pleased to announce the addition of two biomedical engineers, Michael Kisilili and Arthur Oduya to its engineering team and a Sales Executive, John Maina to the newly created Medical Equipment Division. The engineers will assist in the installation, repair and maintenance of our client’s equipment to enable us meet the growing list of clients needs and to continue to provide the best customer service in the industry.

 
New Product Line

New Product Line

Chem-Labs Limited is pleased to announce the addition of Medical Equipment to our existing Laboratory and Point of Care solutions. These include Respiratory and Airway Management systems, Theater and General Hospital equipment.

With this addition Chem-Labs Limited will be able to offer our customers an expanded and more comprehensive and innovative product line in the medical industry.

Chem-Labs prides itself on building long lasting relationships by providing with honesty, and in a sustainable way, the best customer service in the industry, in addition to providing the best brands of quality diagnostic products.

 

New and improved CK-MB liquiUV and CK-MB (NAC-activated) assays

CK-MB liquiUV

 

 

We are pleased to announce an improvement to our CK-MB liquiUV and CK-MB (NAC-activated) assays.
Starting with the lot nos

  • 12100 for CK-MB liquiUV (REFs 12118, 12118150, 12118600)
  • 12004 for CK-MB (NAC-acitvated) (REF 12008)

the immunoinhibition method is now using an antibody with an ultra-high specificity for the CK-M subunit. This new antibody inhibits the CK-M subunit completely. Due to this improvement, HUMAN now offers a new HUMAN calibration and control set for calibration and QC purposes which are specially designed for the improved assays:

  • CK-MB Calibrator Set (REF 13612)
  • CK-MB Control Set (REF 13611)

 The following QC materials and calibrators cannot be used with the above mentioned kits.

  • Serodos (REF 13951)
  • Serodosplus (REF 13151)
  • AUTOCAL (REF 13160)

Any affected CK-MB kit also has a special customer notification. For details on the new CK-MB-specific calibrator and control sets, please contact our customer care on This e-mail address is being protected from spambots. You need JavaScript enabled to view it or call us on +254 20 3741378.
 

Chem-Labs is the exclusive distributor of IMMY products.

CrAg Lateral Flow Assay


Known for its value-added distribution, Chem-Labs is the sole distributor of Immuno-Mycologics(IMMY), Inc products among them the Cryptoccoccus  Lateral Flow Assay CrAg(LFA).

CrAg Lateral Flow Assay is the first and only dipstick test for the detection of cryptococcal antigen. Recently the World Health Organization released Rapid Advice (December 2011 issue) on Diagnosis, prevention and management of cryptococcal disease in HIV-infected Adults, Adolescents and Children where it recommended the use of CrAg LFA for diagnosis of cryptococcal diseases.

The recommendations at a glance contained in this Rapid Advice on diagnosis, prevention and management of cryptococcal disease (meningeal and non-meningeal) in adults, adolescents, and children are based on several guiding principles:

  • Early diagnosis is key to improving mortality due to cryptococcal disease. Health care professionals need to have a low threshold for suspecting cryptococcal meningitis. Countries should prioritise reliable access to rapid diagnostic CrAg assays, either latex agglutination (LA) or lateral flow assay (LFA) for use in cerebrospinal fluid (CSF) and serum or plasma.
  • Early ART initiation is the most important and cost-effective preventive strategy to reduce the incidence and high mortality associated with cryptococcal meningitis. Patients should ideally initiate ART at a CD4 count of 350 cells/mm3, and definitely before a decline in the CD4 cell count to less than 200 cells/mm 3, or development of WHO stage 3 or 4 disease.
  • To promote the use of optimal antifungal treatment regimens and approaches that improve survival, clinical and neurological outcomes, and rapid fungal clearance, while minimising drug related toxicities.
  • Prompt referral for HIV testing and care should be undertaken as soon as appropriate following diagnosis of cryptococcal disease, to facilitate early HIV diagnosis, uptake of ART and retention in care.

To read more about the report on Immy's website click here or the document on WHO's website click here.